Amy P. Abernethy, MD, PhD is the President of Clinical Studies Platforms at Verily, an Alphabet company founded at the convergence of healthcare, data science and technology, where she has responsibility for the company’s Baseline program and other initiatives to support a broad range of clinical trials and real-world evidence (RWE) studies.
Before joining Verily in July, Dr. Abernethy was Principal Deputy Commissioner and Acting Chief Information Officer of the US Food & Drug Administration. While at the FDA, she initiated critical efforts including FDA’s technology and data modernization action plans and FDA’s efforts to leverage real-world data and evidence to address urgent questions during the COVID-19 pandemic.
Dr. Abernethy was Chief Medical Officer and Chief Scientific Officer at Flatiron Health from 2014 to early 2019. Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine, and directed the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute.
Dr. Abernethy went to the University of Pennsylvania as an undergraduate, and then medical school at Duke, where she also did her Internal Medicine residency, a year as Chief Resident, and her hematology/oncology fellowship. She has her PhD from Flinders University in Australia, focused on evidence-based medicine.